Corporate : Registered Office and Plant, Genome Valley Shameerpet, Hyderabad – 500 078 Telangana INDIA
Ph: +91 40 2778 4084
Ph: +91 40 2348 0567
Mob: +91 99480 80567
Fax: +91 40 2348 0560
Website: www.bharatbiotech.com
International Business
For International Business related queries, please write to us at: Email: exports02@bharatbiotech.com
Human Resources
For Careers at Bharat Biotech, please write to us at: E-mail: careers@bharatbiotech.com
Ph: +91 40 2778 4084
Tel: +91 40 2348 0567
Media
For Media related queries, contact: E-mail: media@bharatbiotech.com
Feedback
For Feedback, please write to us at: E-mail: feedback@bharatbiotech.com
Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities. Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets.
Bharat Biotech Campus
Bharat Biotech Campus Building
Bharat Biotech Genome Valley
Bharat Biotech creates innovative vaccines and bio-therapeutics trusted by physicians around the world. We own 160 global patents and our products help people in over more than 65+ countries live to their fullest potential. Our manufacturing facilities are approved by USFDA, KFDA and WHO.
We have delivered over 3 Billion vaccine doses all over the world. Our key priority is to solve the health challenges of the developing world by developing innovative vaccines and therapeutics.
We have 3 WHO pre-qualified vaccines.
World's 1st WHO Pre-Qualified Typhoid Conjugate Vaccine.
World's 1st WHO Pre-Qualified Rotavirus Vaccine.
Our significant R&D investments have yielded several breakthroughs including.
World’s first: Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal).
Rotavirus vaccine from a naturally attenuated strain.
Bharat Biotech Launches ROTAVAC 5D®- Lowest dose volume
rotavirus vaccine in the world launched in December 2019.
Comments